

## Special Issue

# Varicella Zoster Virus: Recent Advances, Risks and Prevention in Infants and Adults in Particular (during Immunomodulating Therapy)

### Message from the Guest Editor

Varicella zoster virus (VZV) is a worldwide pathogen and may result in many complications. As it remains dormant in the nervous system, VZV, which is responsible for herpes zoster in sometimes severe forms, may reactivate later in life. A decrease in the effectiveness of the cellular immune responses due to age, disease, or treatments may explain the increased risk of herpes zoster in populations exhibiting these risk factors. A live attenuated VZV vaccine is available and was approved by FDA in 1995. Vaccination is recommended in some countries like the US and Australia. A live attenuated herpes zoster vaccine has been proven effective and safe in immunocompetent patients. The effectiveness and safety of the herpes zoster vaccine in patients with immunodeficiencies has also been recently demonstrated. This Special Issue will focus on recent research related to the epidemiology of VZV in infants and adults, and recent advances in prevention (vaccination), treatment, and management of varicella and herpes zoster in immunocompromised patients.

### Guest Editor

Prof. Dr. Françoise Lunel-Fabiani  
CHU Angers, France

### Deadline for manuscript submissions

closed (30 November 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/55082](https://mdpi.com/si/55082)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).